CJC-1295/Ipamorelin Blend

CJC‑1295 (No DAC) and Ipamorelin

This peptide combination is utilized in preclinical and early clinical research to mimic endogenous growth hormone (GH) release patterns. Both compounds are investigational and not approved for human or veterinary use; they are supplied for laboratory research only. Current data rely on animal studies, in vitro experiments, and limited human pharmacodynamics analyses, with no therapeutic claims made.

Mechanistic Insights 

CJC‑1295 (No DAC)

• A synthetic analog of Growth Hormone-Releasing Hormone (GHRH) comprising 29 amino acids, designed to resist enzymatic degradation by DPP‑IV; it stimulates pulsatile GH release with a short half-life (~30 minutes). [hkroids.com], [wholesalepeptide.com]
• Binds GHRH receptors on pituitary somatotrophs, triggering cyclic AMP (cAMP) and calcium-second messenger signaling, thus priming the pituitary for GH release. [hkroids.com], [nexusbiolife.com]

Ipamorelin

• A synthetic pentapeptide and selective agonist of the ghrelin receptor (GHS-R1a), known for inducing targeted GH release without significantly affecting ACTH, cortisol, or prolactin. [biolongevitylabs.com], [nordscipeptides.com]
• Amplifies GH pulse amplitude and frequency by binding to the ghrelin receptor on hypothalamic and pituitary cells. [nexusbiolife.com], [nordscipeptides.com]
• Demonstrates high receptor specificity (nanomolar affinity) and favorable preclinical selectivity, making it a precise tool for GH axis studies. [biolongevitylabs.com], [bluumpeptides.com]

Research Applications

GH Axis Modeling

• CJC‑1295 No DAC enables controlled, pulsatile GH stimulation, closely replicating physiological release patterns. [hkroids.com], [nexusbiolife.com]
• Ipamorelin enhances the amplitude and consistency of GH pulses, facilitating detailed exploration of GH’s downstream effects on protein synthesis, metabolism, and tissue repair. [nordscipeptides.com], [newpelican.com]
• Combined use allows sequential activation: Ipamorelin provides an immediate GH pulse, while CJC‑1295 primes the pituitary for sustained GH release over time. [nexusbiolife.com], [biotechpeptides.com]

Tissue and Metabolic Research

• GH pulses mediated by this peptide duo have been linked to lean muscle accretion, enhanced lipolysis, and improved metabolic profiles in animal studies. [nordscipeptides.com], [rawamino.com]
• Post-synchronic activation of the pituitary reveals enhanced cellular protein translation, satellite cell proliferation, and collagen synthesis in rodent muscle and connective tissue models. [nordscipeptides.com], [nexusbiolife.com]

Pharmacodynamic Investigations

• Human PK/PD studies demonstrate that CJC‑1295 No DAC triggers discrete GH pulses, while Ipamorelin adds additional pulse modulation; this enables investigation of GH receptor responsiveness, pulse frequency effects, and IGF‑1 signaling dynamics. [nexusbiolife.com], [bodyspec.com]

Compliance & Disclaimer

• For Research Use Only
• Not FDA or EMA-approved for clinical application
• Evidence restricted to preclinical, in vitro, and early-phase clinical studies
• Safety and efficacy in human therapeutic use are unverified

Key Peer-Reviewed References

• Marinov D., Ph.D. CJC‑1295 DAC vs No DAC: Difference and Use in GH Research. Peptides.org. 2024;21 Jan. [peptides.org], [hkroids.com]
• Nexus Bio Life. CJC‑1295 (No DAC): The Art of Pulsatile Endocrine Research. Nov 2025. [nexusbiolife.com]
• Biolongevity Labs Team. Ipamorelin: The Science Behind the Peptide. July 2025. [biolongevitylabs.com], [peptidedojo.com]
• Nordsci Research. IPAMORELIN Benefits: Mechanisms, Research Signals, and Comparative Insights. Nov 2025. [nordscipeptides.com], [newpelican.com]
• Origin Compounds. CJC‑1295 + Ipamorelin Synergy: Expanded 2025 Research Analysis. Nov 2025. [nexusbiolife.com], [biotechpeptides.com]